On November 17, 2026, biotechnology startup Marrow Therapeutics emerged from stealth with $173 million in Series A and B financing to develop MAR-101, an injectable siRNA transferrin antibody bioconjugate for sickle cell disease and beta thalassemia. Existing gene therapies like Casgevy and Lyfgenia require complex stem cell modification, chemotherapy, and high costs, limiting access in sub-Saharan Africa where most patients live. MAR-101 aims to offer a safer, globally accessible alternative.
Story comments
Loading comments…